Merus Labs announces exclusive licensing agreement with Innocoll Pharmaceuticals
The three products are indicated for the management of painful wounds including diabetic ulcers, venous ulcers, pressure ulcers, full and partial thickness wounds, 1st and 2nd degree burns and dehisced surgical wounds.
The worldwide advanced wound care market is estimated to be worth $5.5bn in 2010. This market is expected to grow by approximately 5.7% to 6% out to 2013.
"We are very pleased to announce this strategic partnership with Innocoll to launch such unique products in Canada. Innocoll is an innovator and world leader in the area of drug delivery and advanced wound care. This partnership with Innocoll will greatly enhance Merus' pipeline of, ready to launch, innovative products in the Canadian market place, significantly enhancing patient care." said Ahmad Doroudian, president & CEO of Merus.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.